Generic erosion of key high-priced brands will see acute coronary syndrome drug market fall 12% to $809 million in 2016

As a result of generic erosion of key high-priced brands, the acute coronary syndrome drug market will decline from approximately $923 million in 2009 to $809 million in 2016 in the USA, France, Germany, Italy, Spain, UK and Japan, says a new report from research and advisory firm Decision Resources. Thereafter, the market will rise to $815 million by 2019 due to the launches and uptake of novel antithrombotic therapies.

The Pharmacor 2010 findings from the topic entitled Acute Coronary Syndrome reveal that the market for post-hospital, prevalent cases of the indication will initially contract from $1.3 billion in 2009 to about $1.2 billion in 2012, due mainly to the generic availability of generic clopidogrel (Sanofi-Aventis/Bristol-Myers Squibb’ Plavix/Iscover).

AstraZeneca's Brilinta/Brilique most likely to change medical practice